Evidence map›Paper›PMID 26974162›Full record

Trial reportPloS one2016

Promiscuous Recognition of a Trypanosoma cruzi CD8+ T Cell Epitope among HLA-A2, HLA-A24 and HLA-A1 Supertypes in Chagasic Patients.

Paola Lasso, Lina Beltrán, Fanny Guzmán, Fernando Rosas, M Carmen Thomas, Manuel Carlos López, John Mario González, Adriana Cuéllar, Concepción J Puerta

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Frontiers in cellular and infection microbiology · 2022
    Review
  3. Review
  4. Frontiers in immunology · 2019
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Paola LassoLaboratorio de Parasitología Molecular, Pontificia Universidad Javeriana, Bogotá, Colombia.
Lina BeltránLaboratorio de Parasitología Molecular, Pontificia Universidad Javeriana, Bogotá, Colombia.
Fanny GuzmánNúcleo de Biotecnología Curauma (NBC), Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.
Fernando RosasInstituto de Arritmias Joseph Brugada, Fundación Clínica Abood Shaio, Bogotá, Colombia.
M Carmen ThomasInstituto de Parasitología y Biomedicina López-Neyra, CSIC, PTS-Granada, Granada, España.
Manuel Carlos LópezInstituto de Parasitología y Biomedicina López-Neyra, CSIC, PTS-Granada, Granada, España.
John Mario GonzálezGrupo de Ciencias Básicas Médicas, Facultad de Medicina, Universidad de los Andes, Bogotá, Colombia.
Adriana CuéllarGrupo de Inmunobiología y Biología Celular, Pontificia Universidad Javeriana, Bogotá, Colombia.
Concepción J PuertaLaboratorio de Parasitología Molecular, Pontificia Universidad Javeriana, Bogotá, Colombia.
Pontificia Universidad Javeriana · COInstituto de Parasitología y Biomedicina "López - Neyra" · ESPontificia Universidad Católica de Valparaíso · CLUniversidad de Los Andes · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTcTLE is a nonamer peptide from Trypanosoma cruzi KMP-11 protein that is conserved among different parasite strains and that is presented by different HLA-A molecules from the A2 supertype. Because peptides presented by several major histocompatibility complex (MHC) supertypes are potential targets for immunotherapy, the aim of this study was to determine whether MHC molecules other than the A2 supertype present the TcTLE peptide. METHODOLOGY/PRINCIPAL

findingsFrom 36 HLA-A2-negative chagasic patients, the HLA-A genotypes of twenty-eight patients with CD8+ T cells that recognized the TcTLE peptide using tetramer (twenty) or functional (eight) assays, were determined. SSP-PCR was used to identify the A locus and the allelic variants. Flow cytometry was used to analyze the frequency of TcTLE-specific CD8+ T cells, and their functional activity (IFN-γ, TNFα, IL-2, perforin, granzyme and CD107a/b production) was induced by exposure to the TcTLE peptide. All patients tested had TcTLE-specific CD8+ T cells with frequencies ranging from 0.07-0.37%. Interestingly, seven of the twenty-eight patients had HLA-A homozygous alleles: A*24 (5 patients), A*23 (1 patient) and A*01 (1 patient), which belong to the A24 and A1 supertypes. In the remaining 21 patients with HLA-A heterozygous alleles, the most prominent alleles were A24 and A68. The most common allele sub-type was A*2402 (sixteen patients), which belongs to the A24 supertype, followed by A*6802 (six patients) from the A2 supertype. Additionally, the A*3002/A*3201 alleles from the A1 supertype were detected in one patient. All patients presented CD8+ T cells producing at least one cytokine after TcTLE peptide stimulation. CONCLUSION/SIGNIFICANCE: These results show that TcTLE is a promiscuous peptide that is presented by the A24 and A1 supertypes, in addition to the A2 supertype, suggesting its potential as a target for immunotherapy.

Indexed as

CD8-Positive T-LymphocytesChagas DiseaseHLA-A1 AntigenHLA-A24 AntigenHLA-A2 AntigenAdultAgedAllelesAntigen PresentationEpitopes, T-LymphocyteFemaleGenotypeHumansMaleMiddle AgedPeptidesEpitopes, T-LymphocyteHLA-A1 AntigenHLA-A24 AntigenHLA-A2 AntigenPeptidesProtozoan Proteins

Identifiers

PMID26974162
PMCPMC4790940
OpenAlexW2462407230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.